Document is current
Any future updates will be listed below
-
Authors
Balius, Trent E. https://orcid.org/0000-0002-6811-4667
Dyba, Marcin https://orcid.org/0000-0001-6311-6877
Kumari, Vandana
Denson, John-Paul
Yi, Ming https://orcid.org/0000-0001-9098-1364
Sharma, Alok K. https://orcid.org/0000-0001-8011-1074
Prakash, Priyanka
Alberico, Emily
Messing, Simon https://orcid.org/0000-0001-8991-2097
Wall, Vanessa https://orcid.org/0000-0002-6972-239X
Chan, Albert H.
Simanshu, Dhirendra K. https://orcid.org/0000-0002-9717-4618
Nissley, Dwight V. https://orcid.org/0000-0001-7523-116X
McCormick, Frank https://orcid.org/0000-0002-6619-7120
Esposito, Dominic
Maciag, Anna E. https://orcid.org/0000-0003-2641-4212
Turner, David M. https://orcid.org/0009-0000-6885-0309
- License Information
-
More Information
Article History
Received: 8 August 2025
Accepted: 16 March 2026
First Online: 30 March 2026
Competing interests
: F.M. is a consultant for Ideaya Biosciences, Kura Oncology, Leidos Biomedical Research, Pfizer, Daiichi Sankyo, Amgen, PMV Pharma, OPNA-IO, and Quanta Therapeutics. He has received research grants from Boehringer–Ingelheim, and is a consultant for and cofounder of BridgeBio Pharma. The remaining authors declare no competing interests.
